Simons Foundation and the JPB Foundation SATB2-associated syndrome (SAS) is an autosomal dominant disorder characterized by significant neurodevelopmental disabilities with limited to absent speech, behavioral issues, and craniofacial anomalies. Previous studies have largely been restricted to case reports and small series without in-depth phenotypic characterization or genotype-phenotype correlations. Seventy two study participants were identified as part of the SAS clinical registry. Individuals with a molecularly confirmed diagnosis of SAS were referred after clinical diagnostic testing. In this series we present the most comprehensive phenotypic and genotypic characterization of SAS to date, including prevalence of each clinical feature, neurodevelopmental milestones, and when available, patient management. We confirm that the most distinctive features are neurodevelopmental delay with invariably severely limited speech, abnormalities of the palate (cleft or high-arched), dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies. This comprehensive clinical characterization will help clinicians with the diagnosis, counseling and management of SAS and help provide families with anticipatory guidance.
of cleft palate, several additional individuals who had alterations in SATB2 as a result of contiguous deletions, intragenic deletions and duplications, and translocations were described (Zarate & Fish, 2017) . Similarly, following the first report of a SATB2 single nucleotide mutation in a 36-year-old man with cleft palate, generalized osteoporosis, and profound intellectual disability, several additional individuals have been described with coding mutations (Bengani et al., 2017; Leoyklang et al., 2007; Zarate et al., 2015; Zarate, Kalsner, et al., 2017) . Consistent features described in individuals with SAS, regardless of the molecular mechanism, include neurodevelopmental disabilities, behavioral abnormalities, and craniofacial anomalies (Zarate & Fish, 2017; Zarate, Kaylor, & Fish, 1993) . From the neurodevelopmental perspective, all individuals described thus far have had developmental delay (DD)/intellectual disability (ID) with severely limited speech (Bengani et al., 2017; Zarate & Fish, 2017; Zarate, Kalsner, et al., 2017) . Behavioral issues may include hyperactivity, sleeping difficulties, autistic features, obsessive tendencies and/or aggressiveness (Zarate, Kalsner, et al., 2017) . Common craniofacial anomalies include palatal abnormalities, micrognathia, and abnormal dentition, most commonly crowding or abnormal dental size/shape (Zarate, Kalsner, et al., 2017) . Other reported features include decreased bone density, hypotonia, growth retardation, and epilepsy (Zarate & Fish, 2017) . While common dysmorphic features have been described in individuals with SAS, facial appearance has not been thought to be distinctive enough to clinically diagnose SAS (Bengani et al., 2017; Zarate, Kalsner, et al., 2017) .
Despite advances in the phenotypic characterization of SAS, longitudinal data in SAS patients have not been available. Furthermore, the vast majority of published reports have been limited to children. Here we report information from the largest number of individuals with SAS and across a broad age range. We provide the phenotype, genotype, and natural history of 72 individuals enrolled through the SAS clinical registry, 46 of whom are not previously published.
| MATERIALS AND METHODS
Participants were recruited into the SAS clinical registry through a referral by a treating clinician, a facilitated inquiry by the testing laboratory, direct contact by a caregiver, or via the SAS support group. Individuals with a molecularly confirmed diagnosis of SAS were eligible for the study. All families reported herein agreed to share clinical information and were enrolled under a research clinical registry protocol approved by the Institutional Review Board of the University of Arkansas for Medical Sciences. For all individuals, medical records including laboratory results were reviewed. Supplementary information was also obtained by parental report through a REDCap™ questionnaire. All families who shared photographs signed consent for publication. Individuals 03, 04, 05, 06, 07, 10, 14, 16, 18, 20, 22, 23, 24, 27, 28, 31, 32, 33, 35, 36, 47, 58, 59, 60 , and 67 were included in previous publications (Bengani et al., 2017; Docker et al., 2014; Schwartz, Wilkens, Noon, Krantz, & Wu, 2017; Tomaszewska et al., 2013; Zarate et al., 2015; Zarate, Kalsner, et al., 2017; Zarate, Steinraths, et al., 2017) .
Analysis and comparison of 2D photographs was conducted using Face2Gene (FDNA, Inc., Boston, MA), an analytic tool that automatically detects and evaluates subtle craniofacial dysmorphology in order to identify a recognizable facial pattern for rare syndromes based on 2D facial photos (Basel-Vanagaite et al., 2016 (Richards et al., 2015) . 
| Statistical analysis

| Perinatal history
In agreement with previous reports, the mean gestational age, weight, and length at birth were normal at 39 weeks (range 32-42 weeks), 3.28 kg (range 1.34-4.53 kg), and 50.5 cm (range 41.5-58.4 cm), respectively. Recurrent ear infections were reported in a few individuals while restrictive lung disease and asthma were infrequent.
| Growth and nutrition
| Endocrine
A single individual was diagnosed with type 1 diabetes while two had hypothyroidism. Although it is unclear how many participants were tested, low vitamin D was diagnosed in five individuals, all of whom were treated.
| Craniofacial and dental anomalies
Palatal and dental abnormalities are consistent features of SAS. In addition to cleft palate (40%), high-arched palate (25%) and bifid uvula (3%) were also present. Micrognathia was present in 46% of affected individuals but none required surgical correction. Dental anomalies (more commonly crowding, large incisors, or abnormal dental shape) were present in all individuals after the first year of life (Figure 1d ).
| Skeletal
Skeletal abnormalities such as pectus excavatum, scoliosis, tibial bowing, and abnormal bone mineralization have been reported occasionally (Boone et al., 2016; Lee et al., 2016; Rainger et al., 2014; Talkowski et al., 2012; Tegay et al., 2009; Zarate et al., 2015; Zarate, Kalsner, et al., 2017) and reaffirmed in this study (Figure 1e ).
The phenotype and genotype description of seven individuals with SAS documented to have low bone mineral density (BMD) and included in this cohort was recently reported (Zarate, Steinraths, et al., 2017) . The high frequency of abnormal mineralization was further supported by six additional individuals who were documented to have a slightly low (−1.9 to −1.1SD) or low (<−2SD for age) BMD by energy X-ray absorptiometry (DXA) scans for 76% (13/17) of those scanned (Supplementary Table S1 ). Similarly, of the 18 individuals who had serum alkaline phosphatase levels performed, 12 (67%, 8 females)
were found to be elevated (Figure 1f ).
| Neurological
Abnormal brain imaging has been reported in several individuals with SAS (Zarate & Fish, 2017; Zarate, Kalsner, et al., 2017) . Magnetic resonance imaging (MRI) of the brain had been performed for 55 individuals in our cohort at a mean age of 2.8 years (range 1-7 years); abnormalities were detected in 47% (26/55) ( Figure 1c ). White matter abnormalities were the most common finding (29%, 16/55), typically described as hyperintense T2/FLAIR white matter signals in the periventricular region. Delayed myelination and enlarged cerebral ventricles were also seen. While these abnormal neuroradiographic findings are common, they are not pathognomonic and do not appear to be prognostic. Seizure disorders, gait abnormalities, and hypotonia have been reported previously (Bengani et al., 2017; Zarate, Kalsner, et al., 2017) and were present in 19, 37, and 74% of our cohort, respectively. Twenty-nine additional individuals underwent electroencephalograms (EEG) with abnormalities detected in 7 (slow background, abnormal wakefulness, or epileptiform discharges), but none were categorized as clinical seizures. For those with seizures, there is no predominant seizure type, and a variety of antiepileptic medications have been used with variable success alone or in combination: levetiracetam (four individuals), valproic acid (two individuals), and single instances of oxcarbazepine, carbamazepine, and lamotrigine use. Dystonia was diagnosed in two females (3%) at 8 and 11 years of age, respectively. The former was managed with trihexyphenidyl first, followed by carbidopa/levodopa with improvement, the latter with no significant improvements after trials of carbidopa/levodopa and baclofen.
| Neurodevelopment
Developmental delay/ID is a hallmark feature of SAS (Bengani et al., 2017; Zarate et al., 2015; Zarate & Fish, 2017; Zarate, Kalsner, et al., 2017) . Key developmental milestones were typically delayed for those old enough to have been assessed (Figure 2a 
| Behavioral phenotype
A broad spectrum of behavioral findings is observed in SAS individuals (Zarate, Kalsner, et al., 2017) . Individuals are often described as having a jovial or friendly personality. In childhood, behavior is commonly described as difficult with episodes of frustration, tantrums, and meltdowns. They can become agitated or have aggressive outbursts (Figure 2e ). These aggressive tendencies are often physical, directed towards self or others, and typically reported in teenagers or adults.
Four individuals (ages 10.5, 14, 18, and 32 years) were on risperidone.
Three had good response, while the fourth needed several additional psychotropic medications over his lifetime to achieve control (valproic acid, haloperidol, sulpiride, quetiapine, chlorprothixene, and fluvoxamine). The potential complexity and worsening of the behavioral ZARATE ET AL.. 
| Facial phenotype
Non-specific craniofacial dysmorphisms have been described in individuals with SAS (Bengani et al., 2017; Zarate, Kalsner, et al., 2017) . In this study, at least minor facial dysmorphic features were described in 47 individuals (65%) (Figure 3 (Figures 4a and 4b; Supplementary Table S2 ). The latter two cases were siblings who were documented to have a 2.9-Mb microduplication that was not present in either parent, suggestive of gonadal mosaicism. These siblings displayed characteristic phenotypic features (neurodevelopmental delay with profound speech delay, dental anomalies, and distinctive facial features) and with their duplication predicted to disrupt SATB2.
Of the remaining 24 individuals, parental studies were performed in 7 individuals and were de novo in each case.
| Intragenic pathogenic variants
Identification of the SATB2 coding variants were made by WES (39/ 46, 85%) or NGS panels (7/46, 15%). When trio analysis was conducted (39 families, including a pair of monozygotic twins), the pathogenic change was found to be de novo in 97% (38/39). In one case, a c.1174G>C (p.G392R) variant was also found in the blood sample of her unaffected father at a low level (not quantified) through WES and Sanger sequencing data. Missense pathogenic variants were the most frequent type of coding pathogenic variant (88% de novo) and mainly located in the CUT1 domain (Figure 4c Table S4 .
| DISCUSSION
SAS is a multi-system disorder caused by alterations of the SATB2 gene, a transcription factor that binds to nuclear matrix-attachment regions (MARs) and activates the transcription of genes that are critical to the development of multiple organ systems, tissues, including the jaw, brain, and skeleton (Britanova et al., 2006; Dobreva et al., 2006; Dobreva, Dambacher, & Grosschedl, 2003; Gyorgy, Szemes, de Juan Romero, Tarabykin, & Agoston, 2008; Jaitner et al., 2016) . In this manuscript we provide the basis to better characterize the natural history and assess genotype-phenotype correlations. We anticipate that as sequencing technologies improve additional individuals with alterations in SATB2 will be identified.
| Prevalence
While the prevalence of SAS is currently unknown, two recent studies have given an estimated frequency of SAS in large cohorts of individuals with undiagnosed intellectual disability/developmental delay of 0.24-0.3% (Bengani et al., 2017; Zarate, Kalsner, et al., 2017) . Given the high frequency of deletions/duplications affecting the SATB2 gene, chromosomal microarray analysis is recommended as a first-tier test followed by a multi-gene panel (SATB2 is included in several clinically available panels targeting ID, seizures, or atypical Rett/Angelman syndrome) or comprehensive genomic sequencing (Zarate et al., 1993) . Of importance, while almost all probands with SAS reported in the literature to date have a de novo genetic alteration, parental mosaicism can rarely be observed. Of the 65 families reported thus far with trio analysis, two instances of mosaicism have now been documented (4.6%): a previously reported case of gonadal mosaicism and the case here described of low level somatic mosaicism in a paternal blood sample (Bengani et al., 2017) . We also describe another instance of presumed germline mosaicism for two siblings with identical microduplications not found in their parents.
| Diagnosis
| Genotype-phenotype correlations
Given the limited number of reported individuals with SAS, no formal genotype-phenotype correlations have been established other than there being a higher frequency of genitourinary anomalies, cardiac defects, and ectodermal changes (other than dental) in individuals with large deletions involving SATB2 and adjacent genes (Zarate & Fish, 2017) .
In this study, we included individuals with large deletions given their overlapping phenotype (and sometimes indistinguishable) with those affected by SAS caused by other genetic alterations. With the exception of HECW2, other genes linked to neurodevelopmental findings that were deleted in some individuals in this study, have a recessive pattern of inheritance. Dominant coding mutations in HECW2 were recently reported to be associated with a neurodevelopmental disorder but haploinsufficiency has not been documented as the mechanism with functional studies (Berko et al., 2017) . A comparison of demographic and phenotypic traits among individuals with different genetic alterations (large deletion, intragenic deletion, disruptive pathogenic variants, 3) are shown in relative size whereas intronic areas are standardized and sized down. SATB2 protein domains according to Pfam. Images were constructed using Illustrator for Biosequence (IBS1.0.1) (Liu et al., 2015) . Missense, nonsense, and frameshift variants are represented by symbols accordingly with each depicting an individual event corresponding to their location within the SATB2 protein. 
| Management and surveillance
There is currently no specific treatment available for SAS and therefore, management is symptomatic. Surveillance guidelines have been previously proposed (Zarate et al., 1993; Zarate & Fish, 2017) . Early in life, the emphasis should be placed on nutritional support for feeding difficulties and management by a cleft/craniofacial team when palatal anomalies are present. A referral for developmental support and special education instruction is needed. While ongoing speech therapy is often reported to be beneficial by families of individuals with SAS, progress can be slow or limited and there is currently no available prospective data to determine adequate frequency of services. Attention should also be placed on communication therapy focusing on facilitated and nonverbal communication strategies. Ongoing surveillance of growth abnormalities, ophthalmological and dental anomalies, and epilepsy is recommended. With the recent report of the high frequency of low BMD in individuals with SAS, evaluation for scoliosis/spine deformity with consideration of screening bone density after 5 years of age is appropriate. Some providers are starting to use inhibitors of bone resorption in the setting of low BMD and osteopenia, but more data will be needed to determine ideal management options (Zarate, Steinraths, et al., 2017) . Current experience with the use of antiepileptic and psychotropic medications is anecdotal and no singular drug is proven to be more beneficial. We provide a brief summary of medications used in this cohort to date as a starting point while additional data are collected.
ACKNOWLEDGMENT
The authors are grateful to all participating families. Clinicians seeking further information or advice on SAS can consult the dedicated website (www.satb2gene.com) or contact the corresponding author. WK Chung received support from the Simons Foundation and the JPB Foundation.
CONFLICTS OF INTEREST
AA is an employee of FDNA, Inc. All other authors declare no conflicts of interest.
